Pfizer withdraws sickle cell disease treatment on risk of …
WEB2 days ago · U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB1 day ago · Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
Regarding OXBRYTA ® - Sickle Cell Disease Association of …
WEB2 days ago · The Sickle Cell Disease Association of America, Inc., (SCDAA) is aware of the recent Pfizer announcement regarding the withdrawal of OXBRYTA ® (voxelotor) for the treatment of sickle cell in all markets. We await further information, and an SCDAA Medical and Research Advisory Committee (MARAC) statement will be forthcoming. We are working diligently through MARAC […]
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB2 days ago · NEW YORK, September 25, 2024--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this ...
Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety ...
WEB1 day ago · Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns.
Pfizer’s Sickle Cell Drug Candidates Not Hit by Oxbryta Pull
WEBEuropean regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease complications in patients who started taking it.
EU regulator recommends suspension of Pfizer's sickle cell …
WEB1 day ago · The European Medicines Agency (EMA) recommended suspending the marketing authorization for Pfizer's sickle cell disease drug Oxbryta on Thursday.
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB2 days ago · Pfizer's decision is based on the totality of clinical data that now indicates the overall benefit of OXBRYTA no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events which require further assessment. Pfizer has notified regulatory authorities about these findings and its decision to voluntarily ...
Pfizer to withdraw sickle cell treatment OXBRYTA from market
WEB1 day ago · Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease (SCD) from worldwide markets. The company is also discontinuing all ...
FDA approves novel treatment to target abnormality in sickle cell ...
WEBToday, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of...